Revita, a new revolutionary treatment technology was developed by Fractyl Laboratories Inc., a US-based company, to make body absorb and process sugar by burning gut. Scientists are using balloon of size less than rice grain in this process. The treatment takes 90 minutes and performed under sedation. Scientists think forming new hormone cells by burning nonhormone producing cells. The new cells formed in our body can release required hormones and subsequently improve processing and absorption of glucose. University College Hospital, London are going to perform first Ravita treatment. But the scientists could not confirm about relief from diabetes after treatment but trials done on 22 Chile citizens were successful.
France based Sanofi developed a new diabetes combination therapy drug, LixiLan, developed with Zealand Pharma. The drug got approval in some countries with the trade name Lyxumia. Two trials in phase III were conducted with the LixiLan drug, LixiLan-O and LixiLan-L, to check the efficacy and safety of the Sanofi's once-daily single injection type combination drug for a period of 30 weeks. Both the studies showed a better reduction in HbA1c from baseline compared with glargine and lixisenatide. The phase III clinical trials of LixiLan diabetes drug were successful. As reported by Sanofi, the side effects are
The results of both trials were included in regulatory submissions in the US and Europe. FDA decision is expected in August and EMA decision early next year.
The ACCORDION trial was based on 1,310 individuals with type 2 diabetes (T2D) and diabetic retinopathy (related to eye and vision). This trial was a continuation of ACCORD trial started 4 years back. Development of diabetic retinopathy was studied on individuals who received intensive blood glucose therapy and kept good blood glucose levels even after 4 years. It was found that the good glycemic control levels failed to reduce the risk for cardiovascular disease but the progression of retinopathy was reduced by one-third. The findings indicate an individual can get positive and long-lasting effects on small blood vessels with the tight control of glycemic levels. Fenofibrate might be good to control diabetic retinopathy and some countries approved it. Emily Chew, M.D., is the lead author of the study, says good glycemia or blood sugar level is good for eye health. The study findings were published in Diabetes Care.
Incidents of nocturnal hypoglycemia in children and adolescents can be reduced by using an automated insulin feedback controller as part of OCL. The study was conducted on Medtronic Android-based PID-IFB closed-loop blood glucose control system for practical usage during multiple nights at a diabetes camp. The product contains
The study results show
The study was conducted by Trang Ly, PhD and the study findings were published in Diabetes Technology & Therapeutics (DTT).
A study conducted by Harvard School of Public Health found that increased consumption of yogurt will lower the risk to type 2 diabetes (T2D). Daily consumption of 28 grams of yogurt will lower risk to type ii diabetes (T2D) by 18%. Yogurt is rich with elements that help us in regulating digestion and intestinal function. They are
Ascensia Diabetes Care manufactures CONTOUR NEXT ONE glucose monitoring systems. A study was conducted by Dr. Timothy Bailey (AMCR Institute, San Diego), the lead investigator, to asses usability of CONTOUR NEXT ONE blood glucose meter with 43 individuals suffering from type 1 diabetes (T1D) and type 2 diabetes (T2D) condition. The study showed that
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.